Interim Report On Civ Recombinant Human Endostatin In Combination With Docetaxel/Cisplatin (Dp)) In Comparison To Dp In The First-Line Treatment Of Phase Iiib/Iv Squamous-Cell Nsclc (Jslcg-001): A Multicenter, Open-Label, Randomized Phase Iii Controlled Study (Nct: 02513342).
JOURNAL OF CLINICAL ONCOLOGY（2019）
AI 理解论文
溯源树
样例
生成溯源树，研究论文发展脉络
Chat Paper
正在生成论文摘要